Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

ClinicalTrials.gov ID: NCT06938867

Public ClinicalTrials.gov record NCT06938867. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2a, Randomized, Double-blind Study to Investigate Safety, Tolerability, PK, PD, and Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplantation Receiving Fluoroquinolone Prophylaxis and Harboring Fluoroquinolone-Resistant Escherichia Coli Pre-Transplant

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1b/2a study in allogenic hematopoietic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC levofloxacin. The study consists of two parts. Part 1 will include 24 randomized and dosed patients. Part 2 will be added with amendment 3 and will include 42 randomized and dosed patients. Thus, approximately 66 patients will be randomized 1:1 to oral dosing of SNIPR001 or matching placebo, to be taken concomitantly with SoC levofloxacin prophylaxis. Subjects will be followed until 100 days post allo-HSCT transplant.

Study identification

NCT ID: NCT06938867
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: SNIPR Biome Aps.; Industry
Enrollment: 66 participants

Conditions and interventions

Conditions

Interventions

Biological · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 4, 2024 (Actual)
Primary completion: Oct 2027 (Estimated)
Completion: Oct 2027 (Estimated)
Last update posted: Oct 8, 2026

2024 – 2027

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 9

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
University of California, San Francisco	San Francisco	California	94118	Recruiting
Johns Hopkins University	Baltimore	Maryland	21218	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Not yet recruiting
University of Minnesota	Minneapolis	Minnesota	55455	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Not yet recruiting
Weill Cornell Medicine	New York	New York	10065	Recruiting
UPMC	Pittsburgh	Pennsylvania	15213-2582	Recruiting
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06938867, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 8, 2026 · Synced Oct 30, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06938867 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →